Navigating high-stakes life science deals requires incisive due diligence to secure your investment or maximise your asset’s value. Our experienced team swiftly identifies critical IP issues and delivers clear and actionable advice. We deliver focused conclusions, providing you with the essential insights needed for confident and timely decisions, all without overwhelming you with irrelevant details.
In-licensing, acquisition, and other M&A activities in the life science sector demands critical due diligence. As a purchaser, it is essential that you understand the IP landscape surrounding a pharmaceutical asset before committing significant funds. For selling parties, ensuring your assets are optimally positioned from an IP perspective is key to maximising value. We are experienced in conducting due diligence for high value pharmaceutical assets and can support your due diligence needs. We identify key issues quickly and efficiently; and provide actionable and pragmatic advice, generally under tight timelines.
We deliver clear, comprehensive IP analysis that highlights strengths and potential risks and can conduct thorough loss of exclusivity, validity, chain of title, and freedom to operate analysis, as well as review of IP provisions. We can assess the alignment between the company’s IP strategy and its business objectives, evaluate the robustness of its freedom-to-operate position, and identify opportunities to strengthen protection. Our attorneys have extensive experience communicating complex IP matters in terms that resonate with business leaders and stakeholders, ensuring you receive practical insights that support your decision-making process.
Rapid initial assessments
You may be looking for a rapid initial assessment of an asset based on public information to inform early-stage discussions, to sign a non-binding term sheet or to decide whether to invest more time evaluating an opportunity. We conduct a focused analysis, prioritising the key areas most likely to dictate the outcome, concentrating our efforts where it will yield the greatest impact. We work to defined budgets and timelines, giving you certainty over costs, timelines and deliverables and allowing you to gain key insights quickly.
In-depth analysis
When you need a detailed review to finalise a deal we can support you through this process. We have particular expertise in pharmaceutical and biotech drug development and commercialisation, regulatory exclusivities, PTE/SPC/paediatric extensions, litigation strategies, entitlement and other legal issues. We avoid impenetrable reports unable to differentiate real issues from noise to provide you with focused conclusions allowing you to make timely decisions.
Contact us today to discuss how our expertise can support your next life science transaction.
